Drug Details
| General Information of the Drug (ID: DR3679) | ||||
|---|---|---|---|---|
| Name |
Sucralfate
|
|||
| Synonyms |
Sucralfato; Ulcerban; Ulcogant; Ulsanic; Sucralfatum; Ulcerlmin; Ulcar; Sucralfatum [INN-Latin]; Sucralfato [INN-Spanish]; OGA-6J; UNII-XX73205DH5; HSDB 3926; XX73205DH5; EINECS 259-018-4; OS 202; DB00364; Sucralfate [USAN:USP:INN:BAN:JAN]; Aluminum, hexadeca-mu-hydroxytetracosahydroxy(mu8-(1,3,4,6-tetra-O-sulfo-beta-D-fructofuranosyl alpha-D-glucopyranoside tetrakis(hydrogen sulfato)(8-)))hexadeca-; Sucrose hydrogen sulfate basic aluminium salt; Sucrose octakis(hydrogen sulfate) aluminum complex; 1,2,3,3',4,4',6,6'-Octa-O-sulfo-beta-D-fructofuranosyl-alpha-D-glucopyranosid aluminium hydroxid-hydrat-salz; alpha-D-Glucopyranoside, beta-D-fructofuranosyl-, octakis(hydrogen sulfate), aluminum complex; Hexadeca-mu-hydroxytetracosahydroxy[mu8-[1,3,4,6-tetra-O-sulfo-beta-Dfructofuranosyl-alpha-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum; Hexadeca-U-hydroxytetracosahydroxy-(U8-(1,3,4,6-tetra-O-sulfo-beta-D-fructofuranosyl-alpha-D-glucopyranoside tetrakis(hydrogen sulfato)(8-))) hexadecaaluminum
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Acne vulgaris [ICD-11: ED80] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
Half-life
The concentration or amount of drug in body reduced by one-half in 6 - 20 hours
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C12H54Al9O55S8
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C(C1C(C(C(C(O1)OC2(C(C(C(O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al]
|
|||
| InChI |
1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;;8*+1;;;;;;;;;;;;;;;;;;;;/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1
|
|||
| InChIKey |
YZPQNHUVIVIUCT-JTJNLBSYSA-F
|
|||
| CAS Number |
CAS 54182-58-0
|
|||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Green tea catechins | Theaceae | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Male NGS/Sea Mongolian gerbils (17 weeks old) were infected with H. pylori (ATCC43504). | |||||
| Experimental
Result(s) |
The CFU of Helicobacter pylori was significantly decreased by GTC-scf. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor 2 (FGF2) | Molecule Info | [3] | |
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | Ras signaling pathway | |||
| 3 | Rap1 signaling pathway | |||
| 4 | PI3K-Akt signaling pathway | |||
| 5 | Signaling pathways regulating pluripotency of stem cells | |||
| 6 | Regulation of actin cytoskeleton | |||
| 7 | Pathways in cancer | |||
| 8 | Proteoglycans in cancer | |||
| 9 | Melanoma | |||
| NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
| Pathway Interaction Database | Glypican 1 network | Click to Show/Hide | ||
| 2 | Angiopoietin receptor Tie2-mediated signaling | |||
| 3 | Integrins in angiogenesis | |||
| 4 | Syndecan-4-mediated signaling events | |||
| 5 | FGF signaling pathway | |||
| Reactome | PI3K Cascade | Click to Show/Hide | ||
| 2 | PIP3 activates AKT signaling | |||
| 3 | FGFR4 ligand binding and activation | |||
| 4 | FGFR3c ligand binding and activation | |||
| 5 | FGFR2c ligand binding and activation | |||
| 6 | FGFR2b ligand binding and activation | |||
| 7 | FGFR3 mutant receptor activation | |||
| 8 | Activated point mutants of FGFR2 | |||
| 9 | Constitutive Signaling by Aberrant PI3K in Cancer | |||
| 10 | POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | |||
| 11 | Syndecan interactions | |||
| 12 | Non-integrin membrane-ECM interactions | |||
| 13 | Phospholipase C-mediated cascade: FGFR1 | |||
| 14 | Phospholipase C-mediated cascade | |||
| 15 | Phospholipase C-mediated cascade | |||
| 16 | Phospholipase C-mediated cascade | |||
| 17 | SHC-mediated cascade:FGFR1 | |||
| 18 | PI-3K cascade:FGFR1 | |||
| 19 | FRS-mediated FGFR1 signaling | |||
| 20 | PI-3K cascade:FGFR2 | |||
| 21 | SHC-mediated cascade:FGFR2 | |||
| 22 | FRS-mediated FGFR2 signaling | |||
| 23 | SHC-mediated cascade:FGFR3 | |||
| 24 | FRS-mediated FGFR3 signaling | |||
| 25 | PI-3K cascade:FGFR3 | |||
| 26 | FRS-mediated FGFR4 signaling | |||
| 27 | SHC-mediated cascade:FGFR4 | |||
| 28 | PI-3K cascade:FGFR4 | |||
| 29 | Negative regulation of FGFR1 signaling | |||
| 30 | Negative regulation of FGFR2 signaling | |||
| 31 | Negative regulation of FGFR3 signaling | |||
| 32 | Negative regulation of FGFR4 signaling | |||
| 33 | RAF/MAP kinase cascade | |||
| WikiPathways | Regulation of Actin Cytoskeleton | Click to Show/Hide | ||
| 2 | Endochondral Ossification | |||
| 3 | Differentiation Pathway | |||
| 4 | Cardiac Hypertrophic Response | |||
| 5 | Syndecan interactions | |||
| 6 | Extracellular matrix organization | |||
| 7 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||
| 8 | PIP3 activates AKT signaling | |||
| 9 | Cardiac Progenitor Differentiation | |||
| 10 | Integrated Pancreatic Cancer Pathway | |||
| 11 | Neural Crest Differentiation | |||
| 12 | miR-targeted genes in squamous cell - TarBase | |||
| 13 | miR-targeted genes in muscle cell - TarBase | |||
| 14 | miR-targeted genes in lymphocytes - TarBase | |||
| 15 | Signaling by FGFR | |||
| 16 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 17 | Angiogenesis | |||